Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20440
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHamblin, Peter S-
dc.contributor.authorWong, Rosemary-
dc.contributor.authorEkinci, Elif I-
dc.contributor.authorFourlanos, Spiros-
dc.contributor.authorShah, Sonali-
dc.contributor.authorJones, Alicia R-
dc.contributor.authorHare, Matthew J L-
dc.contributor.authorCalder, Genevieve L-
dc.contributor.authorEpa, Dilan Seneviratne-
dc.contributor.authorGeorge, Elizabeth M-
dc.contributor.authorGiri, Rinky-
dc.contributor.authorKotowicz, Mark A-
dc.contributor.authorKyi, Mervyn-
dc.contributor.authorLafontaine, Nicole-
dc.contributor.authorMacIsaac, Richard J-
dc.contributor.authorNolan, Brendan James-
dc.contributor.authorO'Neal, David N-
dc.contributor.authorRenouf, Debra-
dc.contributor.authorVaradarajan, Suresh-
dc.contributor.authorWong, Jennifer-
dc.contributor.authorXu, Sylvia-
dc.contributor.authorBach, Leon A-
dc.date2019-03-05-
dc.date.accessioned2019-03-14T22:35:09Z-
dc.date.available2019-03-14T22:35:09Z-
dc.date.issued2019-08-01-
dc.identifier.citationThe Journal of Clinical Endocrinology and Metabolism 2019; 104(8): 3077-3087en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20440-
dc.description.abstractDiabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2i). To determine the incidence, characteristics and outcomes of DKA in SGLT2i-users vs non-users with type 2 diabetes. Retrospective, multi-center, controlled cohort study. All public hospitals in Melbourne and Geelong (combined population 5 million), Australia, from 1 September 2015 - 31 October 2017. Consecutive cases of DKA that developed in the community, or during the course of hospital admission, in patients with type 2 diabetes. In SGLT2i users vs non-users: (i) Odds ratio of DKA developing during hospital admission and (ii) Incidence of DKA. There were 162 cases of DKA (37 SGLT2i users and 125 non-SGLT2i users) with a physician-adjudicated diagnosis of type 2 diabetes. Of these, DKA developed during the course of inpatient admission in 14 (38%) SGLT2i users vs two (2%) non-SGLT2i users, (odds ratio 37.4 [95% CI 8.0-175.9], p<0.0001). The incidence of diabetic ketoacidosis was 1.02/1000 (95% CI 0.74-1.41/1000) in SGLT2i users vs 0.69/1000 (0.58-0.82/1000) in non-SGLT2i users (odds ratio 1.48 (1.02-2.15), p=0.037). Fifteen SGLT2i users (41%) had peak blood glucose <250 mg/dl (14 mmol/l) compared to one (0.8%) non-SGLT2i user (p<0.001). SGLT2i users were more likely to develop DKA as an inpatient compared to non-SGLT2i users. SGLT2i use was associated with a small, but significant increased risk of DKA.en_US
dc.language.isoeng-
dc.titleSGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Journal of Clinical Endocrinology and Metabolismen_US
dc.identifier.affiliationDepartment of Medicine, Monash Universityen_US
dc.identifier.affiliationDepartment of Medicine-Western Precinct, The University of Melbourneen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Eastern Health, Box Hill, Victoria, Australiaen_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDepartment of Diabetes & Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine - Royal Melbourne Hospital, The University of Melbourneen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Monash Health, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Alfred Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Diabetes & Endocrinology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, University Hospital Geelong, Barwon Health, Victoria, Australiaen_US
dc.identifier.affiliationWerribee Mercy Hospital, Princess Highway Werribee, Victoria, Australiaen_US
dc.identifier.affiliationDiabetes Technology Research Group, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine - St Vincent's Hospital Melbourne, The University of Melbourneen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Northern Health, Epping, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Peninsula Health Frankston, Victoria, Australiaen_US
dc.identifier.affiliationPeninsula Clinical School, Monash Universityen_US
dc.identifier.affiliationDepartment of Medicine, Central Clinical School, Monash Universityen_US
dc.identifier.affiliationDepartment of Endocrinology & Diabetes, Western Health, St Albans, Victoria, Australiaen_US
dc.identifier.doi10.1210/jc.2019-00139en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-2372-395Xen_US
dc.identifier.pubmedid30835263-
dc.type.austinJournal Article-
local.name.researcherEkinci, Elif I
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Apr 16, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.